These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15328391)

  • 1. Population pharmacokinetics I: background, concepts, and models.
    Ette EI; Williams PJ
    Ann Pharmacother; 2004 Oct; 38(10):1702-6. PubMed ID: 15328391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
    Ette EI; Williams PJ; Lane JR
    Ann Pharmacother; 2004 Dec; 38(12):2136-44. PubMed ID: 15507495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics II: estimation methods.
    Ette EI; Williams PJ
    Ann Pharmacother; 2004 Nov; 38(11):1907-15. PubMed ID: 15367729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model appropriateness and population pharmacokinetic modeling.
    Ette EI; Williams PJ; Kim YH; Lane JR; Liu MJ; Capparelli EV
    J Clin Pharmacol; 2003 Jun; 43(6):610-23. PubMed ID: 12817524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic principles and techniques of pharmacokinetic modeling.
    Riviere JE
    J Zoo Wildl Med; 1997 Mar; 28(1):3-19. PubMed ID: 9226611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
    Bachmann KA; Lewis JD
    Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics in the 1980s.
    Balant LP
    Clin Ther; 1984; 6(2):112-24. PubMed ID: 6705009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using ontogeny information to build predictive models for drug elimination.
    Alcorn J; McNamara PJ
    Drug Discov Today; 2008 Jun; 13(11-12):507-12. PubMed ID: 18549977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of population pharmacokinetics in current drug labelling.
    Duan JZ
    J Clin Pharm Ther; 2007 Feb; 32(1):57-79. PubMed ID: 17286790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative performance of different stochastic methods to simulate drug exposure and variability in a population.
    Tam VH; Kabbara S
    Diagn Microbiol Infect Dis; 2006 Oct; 56(2):185-8. PubMed ID: 16930922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in pharmacokinetic modeling.
    Ahmad AM
    Biopharm Drug Dispos; 2007 Apr; 28(3):135-43. PubMed ID: 17295411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.
    Sheiner LB
    Drug Metab Rev; 1984; 15(1-2):153-71. PubMed ID: 6745080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
    De Buck SS; Mackie CE
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
    Jelliffe RW; Schumitzky A; Van Guilder M; Liu M; Hu L; Maire P; Gomis P; Barbaut X; Tahani B
    Ther Drug Monit; 1993 Oct; 15(5):380-93. PubMed ID: 8249044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of valproate in Chinese children with epilepsy.
    Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
    Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge-driven approaches for the guidance of first-in-children dosing.
    Edginton AN
    Paediatr Anaesth; 2011 Mar; 21(3):206-13. PubMed ID: 21129100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.